Drug Profile
Adult stem cell therapy-neurological disorders - NeuroNova AB
Latest Information Update: 01 Nov 2005
Price :
$50
*
At a glance
- Originator NeuroNova AB
- Class
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Neurological disorders
Most Recent Events
- 01 Nov 2005 Discontinued - Preclinical for Neurological disorders in Sweden (unspecified route)
- 23 Jun 2004 Preclinical trials in Neurological disorders in Sweden (unspecified route)